IS7885A - HPV-16 og -18 VLP bóluefni - Google Patents

HPV-16 og -18 VLP bóluefni

Info

Publication number
IS7885A
IS7885A IS7885A IS7885A IS7885A IS 7885 A IS7885 A IS 7885A IS 7885 A IS7885 A IS 7885A IS 7885 A IS7885 A IS 7885A IS 7885 A IS7885 A IS 7885A
Authority
IS
Iceland
Prior art keywords
hpv
vlp vaccine
vlp
vaccine
Prior art date
Application number
IS7885A
Other languages
English (en)
Other versions
IS2811B (is
Inventor
Dubin Gary
Innis Bruce
Mohammed Slaoui Moncef
Anne Cecile Wettendorff Martine
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of IS7885A publication Critical patent/IS7885A/is
Publication of IS2811B publication Critical patent/IS2811B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IS7885A 2002-12-20 2005-06-09 Notkun á HPV16 og HPV18 veirulíkum ögnum gegn einni eða fleiri af æxlisvaldandi HPV gerðum 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 IS2811B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20
PCT/EP2003/014562 WO2004056389A1 (en) 2002-12-20 2003-12-18 Hpv-16 and -18 l1 vlp vaccine

Publications (2)

Publication Number Publication Date
IS7885A true IS7885A (is) 2005-06-09
IS2811B IS2811B (is) 2012-11-15

Family

ID=32685362

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7885A IS2811B (is) 2002-12-20 2005-06-09 Notkun á HPV16 og HPV18 veirulíkum ögnum gegn einni eða fleiri af æxlisvaldandi HPV gerðum 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Country Status (28)

Country Link
US (2) US20060251676A1 (is)
EP (1) EP1572233B1 (is)
JP (1) JP5475939B2 (is)
KR (3) KR20050086924A (is)
AP (1) AP2005003347A0 (is)
AR (1) AR042530A1 (is)
AT (1) ATE503492T1 (is)
AU (1) AU2003293942B2 (is)
BE (3) BE2015C068I2 (is)
BR (1) BR0317544A (is)
CA (1) CA2510457C (is)
CY (1) CY1111552T1 (is)
DE (1) DE60336581D1 (is)
DK (1) DK1572233T3 (is)
EA (2) EA009179B1 (is)
EC (1) ECSP055869A (is)
IL (1) IL169085A (is)
IS (1) IS2811B (is)
MA (1) MA27581A1 (is)
MX (1) MXPA05006764A (is)
MY (1) MY144492A (is)
NO (1) NO20052846L (is)
NZ (1) NZ540811A (is)
OA (1) OA13147A (is)
PL (1) PL215257B1 (is)
PT (1) PT1572233E (is)
TW (1) TWI349557B (is)
WO (1) WO2004056389A1 (is)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101926993B (zh) 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
RU2420313C2 (ru) * 2004-06-16 2011-06-10 ГлаксоСмитКлайн Байолоджикалз с.а. Вакцина против вирусов папилломы человека hpv 16 и hpv 18 и по меньшей мере еще одного типа hpv, выбранного из hpv 31, 45 или 52
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006114273A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
CA2606092A1 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
BRPI0811016B1 (pt) * 2007-04-29 2021-09-21 Xiamen Innovax Biotech Co., Ltd. Proteína li truncada do papiloma vírus humano tipo 16
BRPI0815818A2 (pt) 2007-04-29 2016-08-02 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 truncada do papiloma vírus humano tipo 18
WO2010099580A1 (en) 2009-03-05 2010-09-10 Jenny Colleen Mccloskey Treatment of infection
CN102215861B (zh) * 2009-06-19 2014-10-08 艾金株式会社 宫颈癌疫苗
US20170212116A1 (en) 2014-01-31 2017-07-27 Ulisse Biomed Srl Biosensors for the detection of infection and associated maladies
MY195018A (en) 2014-10-24 2023-01-03 Hpvvax Llc Cancer and skin lesion treatment
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
EP3305320B1 (en) * 2015-06-02 2024-02-07 Terumo Kabushiki Kaisha Aluminum-containing adjuvant composition, and vaccine composition containing same
JP2021514666A (ja) 2018-03-06 2021-06-17 プレシゲン，インコーポレイテッド Ｂ型肝炎ワクチンおよびその使用
KR20250136930A (ko) * 2018-03-06 2025-09-16 프레시전 인코포레이티드 사람 파필로마바이러스 백신 및 이의 용도
US11771754B2 (en) * 2018-06-04 2023-10-03 Xiamen University Mutant of L1 protein of human papillomavirus type 18
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
EP1015561B1 (en) 1997-09-05 2006-07-19 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
EP1150712B1 (en) * 1999-02-05 2008-11-05 Merck & Co., Inc. Human papilloma virus vaccine formulations
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
BR0111956A (pt) * 2000-06-26 2003-05-13 Stressgen Biotechnologies Corp Tratamento do vìrus do papiloma humano

Also Published As

Publication number Publication date
PL377710A1 (pl) 2006-02-06
KR20050086924A (ko) 2005-08-30
TW200423957A (en) 2004-11-16
PL215257B1 (pl) 2013-11-29
MA27581A1 (fr) 2005-10-03
EA200701633A1 (ru) 2007-12-28
KR20120123616A (ko) 2012-11-08
HK1085378A1 (en) 2006-08-25
MY144492A (en) 2011-09-30
CA2510457C (en) 2011-12-06
US20060251676A1 (en) 2006-11-09
EP1572233A1 (en) 2005-09-14
NO20052846L (no) 2005-07-13
ATE503492T1 (de) 2011-04-15
WO2004056389A1 (en) 2004-07-08
AU2003293942B2 (en) 2009-12-10
AR042530A1 (es) 2005-06-22
BE2015C069I2 (is) 2024-08-08
CY1111552T1 (el) 2015-08-05
IL169085A (en) 2014-04-30
PT1572233E (pt) 2011-06-07
NZ540811A (en) 2007-03-30
MXPA05006764A (es) 2005-09-08
EA200500834A1 (ru) 2006-02-24
US20050287161A1 (en) 2005-12-29
IL169085A0 (en) 2007-07-04
KR20120118087A (ko) 2012-10-25
BE2015C068I2 (is) 2024-08-08
AP2005003347A0 (en) 2005-06-30
DK1572233T3 (da) 2011-06-27
DE60336581D1 (de) 2011-05-12
EA009179B1 (ru) 2007-12-28
JP2006512413A (ja) 2006-04-13
KR101361769B1 (ko) 2014-02-10
BE2015C067I2 (is) 2024-08-08
IS2811B (is) 2012-11-15
OA13147A (en) 2006-12-13
CA2510457A1 (en) 2004-07-08
TWI349557B (en) 2011-10-01
JP5475939B2 (ja) 2014-04-16
AU2003293942A1 (en) 2004-07-14
BR0317544A (pt) 2005-11-22
EP1572233B1 (en) 2011-03-30
ECSP055869A (es) 2005-09-20

Similar Documents

Publication Publication Date Title
IS7885A (is) HPV-16 og -18 VLP bóluefni
EP1773403A4 (en) VIRAL ADJUVANZIA
NO20054608D0 (no) Influensavirusvaksine
DE602004026540D1 (de) Kurbelwellenmomentmodulator
NO20044326D0 (no) Virale antigener
LT2371856T (lt) Fviii modifikacija, nukreipta į tam tikrą vietą
ATE432056T1 (de) Zervikale zwischenwirbelprothese
DE602004024016D1 (de) Elektroakustische Wandlung
DK1427444T3 (da) West-nil-vaccine
DE60303366D1 (de) Verbessertes bukkalrohr
IS8387A (is) Ónæmisvaldandi samsetningar
IS7831A (is) Bóluefni
NO20033882D0 (no) Vaksine
DE602005014635D1 (de) Impfstoff gegen periodontale krankheit
EP1692279A4 (en) VIRUS PREPARATIONS CONTAINING A CONSERVATIVE
DE60328408D1 (de) Impfstoff
DE502004007433D1 (de) Membranpumpe
DE602004014239D1 (de) Betoniereinrichtung
IS8325A (is) Bóluefni
EP1807116A4 (en) FLU VACCINATION
NO20051561D0 (no) Vaksine
DE112004000547D2 (de) Klappschalung
DK1660123T3 (da) Rotavirusvaccine
EP1948782A4 (en) VACCINE ADJUVANTS
EP1694092A4 (en) ACUTE SPEAKER